Trial Profile

Single-center, Randomized, Double-blind, Placebo-controlled, Sequential Cohort Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAD of FXI-GalNAc-siRNA When Administered Subcutaneously to Healthy Subjects.

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs STP-122G (Primary)
Indications Atrial fibrillation; Deep vein thrombosis; Pulmonary embolism; Thrombosis
Focus Pharmacokinetics
Sponsors Sirnaomics

29 Jul 2026 Planned End Date changed from 1 Jun 2024 to 1 Jun 2027.
29 Jul 2026 Planned primary completion date changed from 1 May 2024 to 1 May 2027.
29 Jul 2026 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com